Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. It was re-introduced into the US market in 2017...Wikipedia

Manufacturer's Website: Mylotarg                                                                                                   Average retail cost: *

* This prescription is provided by your healthcare provider. It cannot be filled in a pharmacy and may be expensive.